Squarepoint’s Altimmune ALT Stock Holding History

Squarepoint’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-26,600	Closed	-$112K	–	3525
2023 Q1	$112K	Buy	+26,600	New	+$316K	﹤0.01%	2948

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Squarepoint's ALT Position: Q1 2026 in Review

Squarepoint reduced its Altimmune (ALT) stake by 48% in Q1 2026, selling an estimated $71.4K and leaving 18,126 shares worth $55.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4132.

Squarepoint first reported a position in ALT in Q3 2016 and has held it in 22 quarters since. The position peaked at $2.2M in Q3 2025. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

Squarepoint held 18,126 shares of Altimmune worth $55.8K as of Q1 2026.
Squarepoint sold 16,823 Altimmune shares in Q1 2026, an estimated $71.4K.
Altimmune made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4132 holding.
Squarepoint first reported a position in Altimmune in Q3 2016 and has held it in 22 quarters since.
Squarepoint's Altimmune position peaked at $2.2M in Q3 2025.
173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.